A single dose of neffy was effective in nearly 90% of patients treated for anaphylactic reactions during oral food challenge and allergen immunotherapy.
Clinical skepticism about the parity in effectiveness of epinephrine delivered via nasal spray vs autoinjector is rooted in fixed assumptions that bear examination, authors say.
Neffy, a needle-free epinephrine nasal spray, showed promise as a safe alternative for treating anaphylaxis in children with food allergies in a phase 3 trial.
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.